Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristin Krukenberg

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Chemistry & Biology|April 25, 2006
Selective kinase inhibition by exploiting differential pathway sensitivityCharles Kung, Denise M Kenski, Kristin Krukenberg, et al.
Cell Metabolism|April 25, 2018
Quantitative Analysis of NAD Synthesis-Breakdown FluxesLing Liu, Xiaoyang Su, William J Quinn, et al.
Molecular Cancer Therapeutics|February 13, 2023
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in TumorsBen Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, et al.
Oncoimmunology|November 10, 2022
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibodyJessica D Weaver, Edward C Stack, Joshua A Buggé, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Chemistry & Biology|April 25, 2006
Selective kinase inhibition by exploiting differential pathway sensitivityCharles Kung, Denise M Kenski, Kristin Krukenberg, et al.
Cell Metabolism|April 25, 2018
Quantitative Analysis of NAD Synthesis-Breakdown FluxesLing Liu, Xiaoyang Su, William J Quinn, et al.
Molecular Cancer Therapeutics|February 13, 2023
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in TumorsBen Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, et al.
Oncoimmunology|November 10, 2022
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibodyJessica D Weaver, Edward C Stack, Joshua A Buggé, et al.
Pageof 1